Safety and Seropositivity after Live Attenuated Vaccine in Adult Patients Receiving Hematopoietic Stem Cell Transplantation

Takatoshi Aoki, Tomohiko Kamimura, Shuro Yoshida, Yasuo Mori, Masanori Kadowaki, Kentaro Kohno, Daisuke Ishihara, Shingo Urata, Takeshi Sugio, Kenjiro Kamezaki, Koji Kato, Yoshikiyo Ito, Tetsuya Eto, Koichi Akashi, Toshihiro Miyamoto

Research output: Contribution to journalArticle

Abstract

Vaccination against vaccine-preventable diseases (VPDs) is highly recommended for hematopoietic stem cell transplantation (HSCT) recipients by several guidelines; however, the safety and seropositivity after live attenuated vaccines remain unclear in adult HSCT recipients. We analyzed titers of antibodies against measles, rubella, mumps, and varicella zoster virus (VZV) from Japanese adult patients who underwent allogeneic HSCT (allo-HSCT) (n = 74), autologous HSCT (auto-HSCT) (n = 39), or chemotherapy (n = 93). The seropositive rates for measles, rubella, mumps, and VZV in allo-HSCT recipients were 20.2%, 36.4%, 5.4%, and 55.4%, respectively. These rates were equivalent to those in auto-HSCT recipients but were significantly lower than those in patients receiving chemotherapy. Antibody titers tended to gradually decrease with time. Twenty-nine allo-HSCT recipients and 8 auto-HSCT recipients received live attenuated vaccines against VPDs for which they tested seronegative. The titers of antibodies against measles, rubella, and mumps significantly increased after 2 shots of vaccine, and the seropositive rate increased up to 19%, 30%, and 27%, respectively. Three patients (8.1%) experienced mild adverse events, which resolved promptly, indicating safe administration of the live attenuated vaccines. In multivariate analysis, history of chronic graft-versus-host disease was significantly associated with high seropositivity for measles as well as high seroconversion rate for measles after vaccination. Live attenuated vaccines against VPDs were safely administered in seronegative adult HSCT recipients. A further observational study is crucial to evaluate the efficacy of vaccination in seronegative HSCT patients.

Original languageEnglish
Pages (from-to)1576-1585
Number of pages10
JournalBiology of Blood and Marrow Transplantation
Volume25
Issue number8
DOIs
Publication statusPublished - Aug 1 2019

Fingerprint

Attenuated Vaccines
Hematopoietic Stem Cell Transplantation
Measles
Safety
Mumps
Rubella
Vaccines
Vaccination
Adult Stem Cells
Human Herpesvirus 3
Antibodies
Drug Therapy
Graft vs Host Disease
Observational Studies
Multivariate Analysis
Guidelines

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Safety and Seropositivity after Live Attenuated Vaccine in Adult Patients Receiving Hematopoietic Stem Cell Transplantation. / Aoki, Takatoshi; Kamimura, Tomohiko; Yoshida, Shuro; Mori, Yasuo; Kadowaki, Masanori; Kohno, Kentaro; Ishihara, Daisuke; Urata, Shingo; Sugio, Takeshi; Kamezaki, Kenjiro; Kato, Koji; Ito, Yoshikiyo; Eto, Tetsuya; Akashi, Koichi; Miyamoto, Toshihiro.

In: Biology of Blood and Marrow Transplantation, Vol. 25, No. 8, 01.08.2019, p. 1576-1585.

Research output: Contribution to journalArticle

Aoki, Takatoshi ; Kamimura, Tomohiko ; Yoshida, Shuro ; Mori, Yasuo ; Kadowaki, Masanori ; Kohno, Kentaro ; Ishihara, Daisuke ; Urata, Shingo ; Sugio, Takeshi ; Kamezaki, Kenjiro ; Kato, Koji ; Ito, Yoshikiyo ; Eto, Tetsuya ; Akashi, Koichi ; Miyamoto, Toshihiro. / Safety and Seropositivity after Live Attenuated Vaccine in Adult Patients Receiving Hematopoietic Stem Cell Transplantation. In: Biology of Blood and Marrow Transplantation. 2019 ; Vol. 25, No. 8. pp. 1576-1585.
@article{6f412f7882f046e7bc49202d4e99f217,
title = "Safety and Seropositivity after Live Attenuated Vaccine in Adult Patients Receiving Hematopoietic Stem Cell Transplantation",
abstract = "Vaccination against vaccine-preventable diseases (VPDs) is highly recommended for hematopoietic stem cell transplantation (HSCT) recipients by several guidelines; however, the safety and seropositivity after live attenuated vaccines remain unclear in adult HSCT recipients. We analyzed titers of antibodies against measles, rubella, mumps, and varicella zoster virus (VZV) from Japanese adult patients who underwent allogeneic HSCT (allo-HSCT) (n = 74), autologous HSCT (auto-HSCT) (n = 39), or chemotherapy (n = 93). The seropositive rates for measles, rubella, mumps, and VZV in allo-HSCT recipients were 20.2{\%}, 36.4{\%}, 5.4{\%}, and 55.4{\%}, respectively. These rates were equivalent to those in auto-HSCT recipients but were significantly lower than those in patients receiving chemotherapy. Antibody titers tended to gradually decrease with time. Twenty-nine allo-HSCT recipients and 8 auto-HSCT recipients received live attenuated vaccines against VPDs for which they tested seronegative. The titers of antibodies against measles, rubella, and mumps significantly increased after 2 shots of vaccine, and the seropositive rate increased up to 19{\%}, 30{\%}, and 27{\%}, respectively. Three patients (8.1{\%}) experienced mild adverse events, which resolved promptly, indicating safe administration of the live attenuated vaccines. In multivariate analysis, history of chronic graft-versus-host disease was significantly associated with high seropositivity for measles as well as high seroconversion rate for measles after vaccination. Live attenuated vaccines against VPDs were safely administered in seronegative adult HSCT recipients. A further observational study is crucial to evaluate the efficacy of vaccination in seronegative HSCT patients.",
author = "Takatoshi Aoki and Tomohiko Kamimura and Shuro Yoshida and Yasuo Mori and Masanori Kadowaki and Kentaro Kohno and Daisuke Ishihara and Shingo Urata and Takeshi Sugio and Kenjiro Kamezaki and Koji Kato and Yoshikiyo Ito and Tetsuya Eto and Koichi Akashi and Toshihiro Miyamoto",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.bbmt.2019.04.006",
language = "English",
volume = "25",
pages = "1576--1585",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Safety and Seropositivity after Live Attenuated Vaccine in Adult Patients Receiving Hematopoietic Stem Cell Transplantation

AU - Aoki, Takatoshi

AU - Kamimura, Tomohiko

AU - Yoshida, Shuro

AU - Mori, Yasuo

AU - Kadowaki, Masanori

AU - Kohno, Kentaro

AU - Ishihara, Daisuke

AU - Urata, Shingo

AU - Sugio, Takeshi

AU - Kamezaki, Kenjiro

AU - Kato, Koji

AU - Ito, Yoshikiyo

AU - Eto, Tetsuya

AU - Akashi, Koichi

AU - Miyamoto, Toshihiro

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Vaccination against vaccine-preventable diseases (VPDs) is highly recommended for hematopoietic stem cell transplantation (HSCT) recipients by several guidelines; however, the safety and seropositivity after live attenuated vaccines remain unclear in adult HSCT recipients. We analyzed titers of antibodies against measles, rubella, mumps, and varicella zoster virus (VZV) from Japanese adult patients who underwent allogeneic HSCT (allo-HSCT) (n = 74), autologous HSCT (auto-HSCT) (n = 39), or chemotherapy (n = 93). The seropositive rates for measles, rubella, mumps, and VZV in allo-HSCT recipients were 20.2%, 36.4%, 5.4%, and 55.4%, respectively. These rates were equivalent to those in auto-HSCT recipients but were significantly lower than those in patients receiving chemotherapy. Antibody titers tended to gradually decrease with time. Twenty-nine allo-HSCT recipients and 8 auto-HSCT recipients received live attenuated vaccines against VPDs for which they tested seronegative. The titers of antibodies against measles, rubella, and mumps significantly increased after 2 shots of vaccine, and the seropositive rate increased up to 19%, 30%, and 27%, respectively. Three patients (8.1%) experienced mild adverse events, which resolved promptly, indicating safe administration of the live attenuated vaccines. In multivariate analysis, history of chronic graft-versus-host disease was significantly associated with high seropositivity for measles as well as high seroconversion rate for measles after vaccination. Live attenuated vaccines against VPDs were safely administered in seronegative adult HSCT recipients. A further observational study is crucial to evaluate the efficacy of vaccination in seronegative HSCT patients.

AB - Vaccination against vaccine-preventable diseases (VPDs) is highly recommended for hematopoietic stem cell transplantation (HSCT) recipients by several guidelines; however, the safety and seropositivity after live attenuated vaccines remain unclear in adult HSCT recipients. We analyzed titers of antibodies against measles, rubella, mumps, and varicella zoster virus (VZV) from Japanese adult patients who underwent allogeneic HSCT (allo-HSCT) (n = 74), autologous HSCT (auto-HSCT) (n = 39), or chemotherapy (n = 93). The seropositive rates for measles, rubella, mumps, and VZV in allo-HSCT recipients were 20.2%, 36.4%, 5.4%, and 55.4%, respectively. These rates were equivalent to those in auto-HSCT recipients but were significantly lower than those in patients receiving chemotherapy. Antibody titers tended to gradually decrease with time. Twenty-nine allo-HSCT recipients and 8 auto-HSCT recipients received live attenuated vaccines against VPDs for which they tested seronegative. The titers of antibodies against measles, rubella, and mumps significantly increased after 2 shots of vaccine, and the seropositive rate increased up to 19%, 30%, and 27%, respectively. Three patients (8.1%) experienced mild adverse events, which resolved promptly, indicating safe administration of the live attenuated vaccines. In multivariate analysis, history of chronic graft-versus-host disease was significantly associated with high seropositivity for measles as well as high seroconversion rate for measles after vaccination. Live attenuated vaccines against VPDs were safely administered in seronegative adult HSCT recipients. A further observational study is crucial to evaluate the efficacy of vaccination in seronegative HSCT patients.

UR - http://www.scopus.com/inward/record.url?scp=85065081965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065081965&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2019.04.006

DO - 10.1016/j.bbmt.2019.04.006

M3 - Article

VL - 25

SP - 1576

EP - 1585

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 8

ER -